Lantheus
LNTH
Hutchmed (China)
HCM
Workday
WDAY
DexCom
DXCM
Halozyme Therapeutics
HALO
US Stock MarketDetailed Quotes
ORGO Organogenesis
- 3.250
- +0.040+1.25%
Trading Feb 26 12:36 ET
408.61MMarket Cap-65.00P/E (TTM)
3.310High3.200Low70.17KVolume3.240Open3.210Pre Close228.75KTurnover0.13%Turnover Ratio81.25P/E (Static)125.73MShares4.57052wk High1.47P/B176.88MFloat Cap2.16552wk Low--Dividend TTM54.42MShs Float310.900Historical High--Div YieldTTM3.43%Amplitude1.795Historical Low3.260Avg Price1Lot Size
Organogenesis News
Earnings Preview: ORGO to Report Financial Results Post-market on February 27
Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025
Organogenesis Holdings Leads These 3 US Penny Stocks
The Colossal Foundation Donates $1.5M to the Wyss Institute at Harvard University to Advance Artificial Womb Technology for Wildlife Conservation
Organogenesis Files to Sell 130K Shares of Common Stock for Holders
Insider Sale: President and CEO of $ORGO (ORGO) Sells 18,416 Shares
Morgan Stanley Initiates Organogenesis(ORGO.US) With Hold Rating, Announces Target Price $4
Organogenesis Assumed With an Equal Weight at Morgan Stanley
Organogenesis Announces Plans To Expand Manufacturing Capacity With A Long-Term Lease A Biomanufacturing Facility Located At 100 Technology Way In Smithfield, Rhode Island
US Manufacturing Index Rises To 43, Highest Since 2020
Organogenesis Holdings Inc. Applauds CMS Decision on Coverage for Skin Substitute Products for Diabetic and Venous Ulcers
Organogenesis 'Commends' Final Local Coverage Determinations
Press Release: Organogenesis Commends Final LCDs
Morgan Stanley Sticks to Their Hold Rating for Organogenesis Holdings (ORGO)
Cantor Fitzgerald Maintains Organogenesis(ORGO.US) With Buy Rating, Raises Target Price to $3.8
Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday
Organogenesis Holdings Secures $130M Investment for Growth
BTIG Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $6
Organogenesis Reports Robust Third Quarter Growth
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript Summary